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AZATHIOPRINE and its metabolite 6-mercaptopurine are
effective  in  the  treatment  of  inflammatory  bowel
disease. They are mostly used for reduction of the use
of  steroids,  maintenance  therapy  after  remission
induction by cyclosporin and treatment of fistulae in
Crohn’s disease. Adverse effects occur in about 15%
of  patients.  The  main  side  effects  are  pancreatitis,
allergic reactions,  fever and  bone marrow suppres-
sion.  Symptoms,  management  and  prevention  are
discussed. A blood monitoring schedule is suggested.
Azathioprine and 6-mercaptopurine seem to be safe
in pregnancy. There may be a slight increased risk for
developing a non-Hodgkin’s lymphoma.
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Introduction
Azathioprine (AZA) and its metabolite 6-mercaptopur-
ine  (6-MP)  have  been  used  in  the  treatment  of
inflammatory bowel disease (IBD) for more than 30
years.1 However the more widespread use of AZA/
6-MP in the treatment of IBD is of more recent origin.
The reason for this has been a longstanding debate on
the  efficacy  of AZA/6-MP  in  IBD.  Reasons  for  the
doubt  about  efficacy  were  the  relative  long  time
before effects are seen, the different doses used, the
different  study  designs  and  the  small  number  of
patients in some trials. AZA and 6-MP are slow acting
drugs and the optimum effect may only be expected
after 12–17 weeks of treatment.
In 1995  a  meta-analysis of  nine  randomized, pla-
cebo-controlled clinical trials on the use of AZA/6-MP
therapy in Crohn’s disease was published. The esti-
mated  common  odds  ratio  of  response  for  active
disease was 3.09 (95%  CI, 2.45–3.91) and for main-
tenance therapy 2.27 (95% CI, 1.76–2.93). The steroid
sparing  effect  had  an  odds  ratio  of  3.69  (95%  CI,
2.12–6.42)  in  active  disease  and  4.64  (95%  CI,
1.00–21.54) in quiescent disease. The improvement
of fistulae with this therapy had an odds ratio of 4.44
(95%   CI,  1.50–13.20).  In  conclusion  this  analysis
showed  that  AZA/6-MP  is  effective  in  active  and
quiescent Crohn’s disease.2
This paper will deal with the safety of AZA/6-MP in
the treatment of IBD. Adverse effects and questions
relating  to  fertility  and  pregnancy  are  discussed. A
monitoring  schedule  to  minimize  the  risk  of  bone
marrow suppression is suggested.
Indications and Dosage
The main indications for the use of AZA in IBD are
(1)  steroid  sparing  treatment,  (2)  maintenance  of
remission, (3)  maintenance  therapy after  treatment
with  cyclosporin,  (4)  Crohn’s  disease  with  fistulae
and  (5)  chronic  active  ulcerative  colitis.  Though
Candy reported the successful use of AZA as a single
drug  treatment  in  remission  induction  and  main-
tenance  of  remission  of  Crohn’s  disease,  AZA  is
mostly  used  in  combination  with  mesalasine  or
topical steroid therapy or both.3 The recommended
dose for IBD is 1.5–2.5mg/kg per day.2–4 Recently a
high dose induction schemes using up 40mg AZA/kg
over  36h  indicated  that  the  time  to  response  in
Crohn’s disease could be shortened.5 However such
an  induction  scheme  has  the  risk  of  serious  side
effects, especially in patients who lack the enzyme
thiopurinemethyltranferase. This enzyme is responsi-
ble  for  converting  one  of  its  two inactive  metabo-
lites. A  low  or  absent  activity  of  this  enzyme  will
result in higher concentrations of the active metabo-
lites 6-thioguanine nucleotides (6-TGN). Larger stud-
ies are  being  performed to  clarify  the risk, benefit
and safety of such  a high dose induction scheme.6
Until such studies are completed the use of a high
dose induction scheme should be limited to a study
setting.  Patients  treated  with  this  scheme  should
0962-9351/98/030141-04 $9.00 © 1998 Carfax Publishing Ltd 141
Mini-Review
Mediators of Inflammation, 7, 141–144 (1998)probably be tested for low thiopurinemethyltranfer-
ase activity prior to treatment.
Adverse Effects
Adverse  effects  serious  enough  to  stop AZA/6-MP
treatment may occur in 8–15% of IBD patients.2–4
The most common side effects of AZA/6-MP treat-
ment are pancreatitis, allergic reactions, gastro-intesti-
nal  complaints,  hepatitis  and  bone  marrow
suppression. There seems to be no difference in the
type  of  side  effects  between  AZA  and  6-MP .  It  is
therefore possible to use data from studies in which
either one or both have been studied.
Pancreatitis
Of 396 IBD patients treated with 6-MP and followed
up  for  a  mean  of  60.3  months,  13  patients  (3.3% )
developed a clinical pancreatitis.4The meta-analysis of
Pearson  et  al. showed  an  overall  occurrence  of
pancreatitis  of  1.3%.2 Others  have  reported  pan-
creatitis  to  occur  in  0–7%  of  patients. The  mean
duration between the start of the medication and the
first symptoms the pancreatitis was 23 days, with a
range of 1–32 days. However one patient developed a
6-MP  related  pancreatitis  after  6  months  of  treat-
ment.4,7The clinical course of the pancreatitis is mild.
When  the  AZA/6-MP  medication  is  discontinued
immediately  when  pancreatitis  is  diagnosed,  symp-
toms disappear and serum amylase values return to
normal within a mean of 3 days (range 1–11 days). No
complications such as chronic pancreatitis or pseudo-
cyst formation have been reported. No relation could
be established between the pancreatitis and the dose
of 6-MP or AZA, concurrent medication, other side
effects  such  as  bone  marrow  suppression  or  the
severity of the IBD.2,4,7
Rechallenge with 6-MP or AZA after the patient had
recovered from pancreatitis resulted in a relapse of
the pancreatitis in seven of the seven cases. Desensi-
bilization  was  tried  in  three  patients  without
success.4
The usefulness of screening the  amylase level in
blood or urine has not been evaluated. However the
rapid onset of the pancreatitis will make the chance
of  preventing  clinical  symptoms by early detection
rather  small.  Secondly  some  patients  develop  a
transient increase of the amylase level without clinical
symptoms. The interpretation of screening data would
therefore be difficult. This, taken together with the
usual mild course and quick resolution of symptoms,
suggests that laboratory tests for pancreatitis should
only be performed on clinical indication.
Allergic reactions
Allergic  reactions,  including  fever,  skin  rash  and
arthritis  have  been  reported  in  up  to  6%  of  IBD
patients  treated  with  AZA/6-MP .  Patients  usually
become symptomatic  within 3 weeks of treatment.
Symptoms  are  mostly  mild  but  can  be  severe.  A
hypersensitivity  syndrome  with  multi-organ  failure
has  occasionally  been  associated  with  the  use  of
AZA.2,4,8 Recovery  occurs  within  a  few  days  after
discontinuation of the treatment.4 Rechallenge is not
useful and could even induce a severe hypersensitiv-
ity  syndrome.9 Successful  desensitization  for  aza-
thioprine skin rash in a patient with Crohn’s disease
has been reported recently.10
Two patients were recently described who devel-
oped a photosensitive rash while being treated with
AZA  for  10  and  14  days. The  clinical  diagnosis  of
pellagra was made. The dietary history showed a well
balanced diet and an adequate nicotinic acid intake.
The rash disappeared after nicotinic acid suppletion.
6-MP can cause a partial  inhibition of the nicotinic
acid pathway, leading to pellagra in patients who have
already  a  marginal  nicotinic  acid  status  due  to
malabsorption caused by the IBD.11
Hepatitis and gastro-intestinal complaints
Toxic hepatitis due to AZA/6-MP is rare in patients
being  treated  for  IBD.  Present  et  al.4 reported  a
patient  who  developed  a  toxic  hepatitis  on  6-MP ,
which  resolved completely  after  withdrawal  of  the
drug. A year later the patient rechallenged himself by
restarting  the  drug  to  treat  his  colitis. The  colitis
responded well, but the hepatitis recurred within 6
weeks.  Symptoms  disappeared  after  withdrawal  of
the drug.4 Nausea, severe enough to stop treatment,
has been reported in 1.3%. Mild symptoms of nausea
or abdominal discomfort occur quite often after the
start of the treatment with AZA/6-MP . The complaints
are usually transient and dividing the dose into two or
three a day may be helpful.
Bone marrow suppression
One of the most serious adverse effects of AZA/6-MP
treatment in IBD is suppression of the bone marrow.
All three cell lines can be affected. A severe leukope-
nia, thrombocytopenia or anaemia or a combination
can be the result. Present reported a leukopenia of
less then 2.5 3 109/l in 2%  of the patients treated with
6-MP  1.5mg/kg/day.  The  meta-analysis  of  Pearson
gave  a  mean  of  1.7%.  One  patient  died  due  to
septicaemia.2,4
Candy et al.3 reported a dose reduction of AZA due
to a leukocyte count of less than 4 3 109/l in 13 of 33
patients. All  returned to  white  cell  count  levels  of
above 4 3 109/l after dose reduction. No-one had to
discontinue the treatment.3
A more detailed retrospective study was carried out
in 739 patients, who were treated for IBD with an
initial dose of AZA 2mg/kg/day. The study covered a
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blood  cell  count  less  than  3.0  3 109/l)  and/or  a
thrombocytopenia  (platelet  count  less  than  100  3
109/l) was recorded in 37 patients (5% ). Nine had a
white cell count of less than 2.0 3 109/l. Three of
these nine patients were pancytopenic. Two of them
died from septicaemia and the other had a pneumonia
but recovered within a week. Another two patients
with only severe leukopenia were symptomatic too.
Both  had  a  mild  upper  respiratory  infection  and
recovered within a few days. Isolated thrombocytope-
nia was never clinically severe. Bone marrow toxicity
from AZA/6-MP treatment may develop at any time. In
the  mentioned  study  the  mean  time  at  which  the
bone  marrow  suppression  was  diagnosed  was  9
months with a range of 0.5–132 months of treatment.
Myelosuppression  may  occur  suddenly  or  over  a
period of several months.1 No correlation was shown
between  bone  marrow  suppression and the  cumu-
lative dose of AZA.3,4 A negative correlation seems to
exist  between  the  white  blood  cell  count  and the
effect of the treatment.3,4
Regular  monitoring  of  the  full  blood  count  is
recommended. However monitoring schedules differ
in the different studies. The most practical and safe
schedule seems to be a 2-weekly monitoring for the
first 3 months, followed by a bi-monthly monitoring
schedule. The  blood  tests  could  be  carried  out  at
primary health care level, provided proper guidelines
have  been  furnished. An  example  of  a  monitoring
schedule is given in Table 1.
Fertility and Pregnancy
Many IBD patients are in the reproductive phase of
their lives. This makes questions about the impact of
AZA/6-MP  treatment  on  fertility  and  pregnancy  of
great  importance.  The  influence  of  AZA/6-MP  on
human fertility has not been studied. However there
are indications that it does not cause infertility.12,13
The effect of the paternal use of AZA/6-MP at the
time of conception on the outcome of the pregnancy
is not entirely clear. The limited data available suggest
it  to  be  safe. There  could  be  some  concern  from
theoretical  point  of  view  and  from  some  animal
studies.  However  this  is  not  supported  by  clinical
evidence.13 Clinical experience with the use of AZA/
6-MP during pregnancy is derived mostly from renal
transplant recipients. In this group the use of AZA/
6-MP during pregnancy may be associated with fetal
growth retardation and prematurity. There seems to
be no marked increase in the frequency of congenital
anomalies or fetal death.13 The use of AZA/6-MP for
IBD  does  not  warrant  a  mandatory  termination  of
pregnancy, as sometimes has been advised.14
It is advisable to discuss the small potential risks of
the use of AZA/6-MP with the patient and the spouse
before conception. In this discussion the indication
for which AZA/6-MP was prescribed and the risk of
other drugs like high steroids and the risks of a flair
up of the IBD should be pointed out as well.
Neoplasms
Are IBD patients, who are treated with AZA/6-MP for
years, at greater risk to develop more neoplasms then
the general population? This risk seems to be rather
small. There is a possible association between AZA/
6-MP  use  and  the  development  of  a  (cerebral)
lymphoma.  If  corrected  for  factors  as  age  and
underlying  disease  no  other  associations  could  be
made.4,15,16
Conclusions
AZA/6-MP are effective in the treatment of IBD. They
can be used as steroid sparing drugs, as maintenance
drugs after remission induction with cyclosporin and
for fistulae in Crohn’s disease. The high  dose intra-
venous induction treatment should only be used in a
research  setting  until  more  data  are  available. The
effective dose for 6-MP is 1.5mg/kg/day and for AZA
1.5–2.5mg/kg/day. The optimal effect is only reached
after 3–4 months. The optimal length of treatment has
still to be established. In about 15% of the patients the
drug  has  to  be  discontinued  because  of  adverse
effects.  The  main  adverse  effects  are  pancreatitis,
allergic reactions and bone marrow suppression. In
pancreatitis or allergic reactions rechallenge seems to
be of no use and could even be hazardous. To prevent
Azathioprine in IBD
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Table 1. Monitoring schedule azathioprine/6-mercaptopurine
treatment for IBD
First 3 months: haemoglobin, leukocytes, platelets every 2
weeks, followed by Haemoglobin, leukocytes, platelets
every 2 months
Haemoglobin ¯ 1–2mmol/l or
Leukocytes 3 <–<4 3 109/l or
Platelets 70 <–<100 3 109/l
Action: Reduce dose to 50% .
Check blood values weekly.
If further reduction, stop treatment and follow
undermentioned scheme.
If values normalize, increase dose to 100% .
Check blood values weekly for 1 month.
In case of a relapse, reduce dose to 50%
permanently.
If no relapse, follow regular monitoring schedule.
Haemoglobin ¯ < 2mmol/l or
Leukocytes <3 3 109/l or
Platelets < 70 3 109/l
Action: Stop treatment.
Check blood values weekly.
If values normalize, restart with 50% of the initial
dose.
Check blood values weekly for 1 month.
In case of relapse, stop treatment permanently.
If no relapse, follow regular monitoring schedule.severe bone marrow toxicity full blood count mon-
itoring should be performed regularly. A schedule has
been  suggested  in  this  paper.  However  clinicians
should be alert to a sudden myelosuppression, which
can occur despite regular monitoring.
When AZA/6-MP is the most effective drug for the
treatment of IBD there is not enough clinical evidence
to  advise  against  fathering  a  child  or  to  become
pregnant. Pros and cons should be discussed with the
patient.
There may be a slight increased risk for developing
a non-Hodgkin’s lymphoma. The efficacy and safety of
local AZA applications  are  presently  being  studied.
This could be a promising development in the local
treatment of IBD.
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